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5-Lipoxygenase-mediated mitochondrial damage and apoptosis mononuclear cells (PBMC) significantly accelerates and
of mononuclear cells in ESRD patients. worsens renal injury [1, 2]. Both ROS formation and cyto-
Background. 5-Lipoxygenase activity is enhanced in periph- kine release involve the activity of 5-lipoxygenase, whicheral blood mononuclear cells (PBMC) from end-stage renal
is enhanced in PBMC of ESRD patients [4]. The “lipoxy-disease (ESRD) patients on maintenance hemodialysis (HD),
genase pathway” converts arachidonic acid into leuko-leading to lipoperoxidation and reactive oxygen species forma-
tion. These effects are prevented by vitamin E, which inhibits trienes and lipoxins [5], and activation of the 5-lipoxygen-
5-lipoxygenase activity. The present study was designed to test ase isozyme has been demonstrated in the early phase
the possibility that 5-lipoxygenase activation might cause mito- of apoptosis (programmed cell death [PCD]) [6]. Inter-chondrial damage and cytochrome c release, ultimately leading
estingly, this gene-controlled type of death, which is exe-PBMC to apoptosis.
cuted through factors released from damaged mitochon-Methods. Apoptosis, mitochondrial uncoupling, and cyto-
chrome c release were investigated in PBMC from 16 healthy dria [6], has also been recently associated with uremia
volunteers and 16 ESRD patients on maintenance HD with and ESRD [7]. On the other hand, vitamin E-modified
cuprammonium rayon (CL-S) membranes in a two-step cross- multilayer HD filters have been shown to be highly bio-over study: after a four-week treatment with vitamin E-coated
compatible, due to their ability to scavenge ROS and tocuprammonium rayon (CL-E) membranes, and again after a
abolish the overproduction of pro-inflammatory cytokinesfour-week treatment with oral vitamin E.
Results. Compared to healthy controls, PBMC from ESRD by PBMC [2, 8]. In this context, it is noteworthy that
patients showed athreefold increase in mitochondrial uncou- vitamin E inhibits 5-lipoxygenase activity in ESRD pa-
pling and cytochrome c release (within 4 and 8 hours, respec-
tients subjected to HD [4]. Here, we investigated whethertively), followed by a threefold increase in apoptotic body
5-lipoxygenase-mediated oxidative stress may be involvedformation (within 48 hours). Regardless of the administration
route, vitamin E reduced mitochondrial uncoupling, cyto- in mitochondrial damage and PCD of mononuclear cells
chrome c release and apoptosis of mononuclear cells, as did from ESRD patients on maintenance HD. We also com-
the 5-lipoxygenase inhibitor eicosatetraynoic acid. Conversely, pared vitamin E-coated to conventional dialyzers in or-
the cyclooxygenase inhibitor indomethacin was ineffective.
der to ascertain their potential role in oxidative stress-Conclusions. Reported data suggest that the 5-lipoxygenase
induced apoptosis of PBMC.branch of the arachidonate cascade is only responsible for
mitochondrial disruption and apoptosis of PBMC of ESRD
patients, and that vitamin E may be helpful in the control of
METHODSoxidative stress-related disease in these subjects, independent
of the administration route. Patients
After informed consent was obtained, sixteen ESRD
patients (aged 54 5 years) under maintenance HD fromOxidative stress appears to contribute to end-stage
60 5 months, and sixteen age-matched healthy controlsrenal disease (ESRD) and related kidney disorders [1, 2],
(52  5 years) were enrolled into the study. ESRD pa-and uremic syndrome in hemodialysis (HD) patients is
tients and healthy controls were not matched for concur-closely associated to injury by reactive oxygen species
rent cardiovascular disease. However, neither ESRD pa-(ROS) and a highly peroxidative state [3]. Moreover, the
tients nor healthy controls experienced acute myocardialrelease of inflammatory cytokines by peripheral blood
infarction or cerebrovascular accident before the begin-
ning of the study. Nine subjects in the patient group and
three in the control group had taken antihypertensiveKey words: apoptosis, cytochrome c, hemodialysis, 5-lipoxygenase, mi-
tochondria, peripheral blood mononuclear cells, vitamin E. medications, three subjects in the patient group, and one
in the control group, had taken -hydroxymethylgluta- 2003 by the International Society of Nephrology
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Table 1. Mitochondrial uncoupling, cytochrome c release, and apoptosis of PBMC from ESRD patients on maintenance HD
Mitochondrial Cytochrome c Apoptotic body
uncoupling release formation
Subjects % of control % of control % of control
Healthy controls 100 100 100
ESRD 35035a 30030a 33030a
CL-E 20020b 20020b 19020b
Washout 37036a 33032a 44042a
Oral vitamin E 22021b 20020b 20020b
Washout  vitamin E 28027c 25025c 29030c
Washout  ETYA 24024c 19020c 23024c
Washout  INDO 35035 32032 44042
Washout  Z-DEVD-FMK 35035 30030 24024c
Patients (N  16) were treated with conventional cuprammonium rayon (CL-S) membranes, before ESRD and after CL-E, a four-week treatment with multilayer
vitamin E-coated cuprammonium rayon membranes, followed by a four-week washout with CL-S filters and by another four-week treatment with CL-S filters and
oral vitamin E 600 mg daily. Mononuclear cells from washout patients were analyzed also in the presence of 50 M vitamin E, 10 M ETYA, 100 M indomethacin,
or 50 M Z-DEVD-FMK. Mitochondrial uncoupling, cytochrome c release, and apoptotic body formation were measured after four hours, eight, and 48 hours of
culture, respectively. Statistical analysis was performed using Student’s t test.
aP  0.01 compared with healthy control
bP  0.05 compared with healthy control
cP  0.05 compared with washout
P  0.05 in all other cases.
ryl-GA (HMGCoA) reductase inhibitors. All ESRD up to 48 hours in RPMI 1640 medium containing 10%
patients received a standard bicarbonate dialysis sched- heat-inactivated fetal calf serum [7]. Apoptotic body for-
ule of four hours, three times weekly, using 1.3 square- mation in dead cells was then quantified by flow cyto-
meter cuprammonium rayon membranes (CliransS15, metric analysis in a FACScalibur Flow Cytometer (Bec-
CL-S), for at least six months. The cause of ESRD was ton Dickinson), stained with propidium iodide (50 g/mL,
chronic glomerulonephritis in nine patients, nephroangi- pretreated also with 15,000 U/mL RNase to reduce noise;
osclerosis in five, and polycystic kidney disease in two. from Sigma Chemical Co., St. Louis, MO), as reported
Healthy controls showed normal parameters of renal [9]. Control PBMC were treated with vehicle alone and
function. All patients and healthy controls were non- contained less than 4.0  1.0 apoptotic bodies for every
smokers for at least one year. Both ESRD patients and 100 cells analyzed [9]. Mitochondrial uncoupling of PBMC
controls were on a free diet with a normal and constant
was evaluated by flow cytometric analysis in a FACScali-intake of essential fatty acids, and none of them took
bur Flow Cytometer, using the fluorescent probe JC-1any drug with an established or potentially oxidizing
(20 M, dissolved in dimethylsulfoxide; from Moleculareffect. In particular, any treatment with HMGCoA re-
Probes, Eugene, OH) [9].ductase or ACE inhibitors, or with angiotensin (AT)
The amount of cytochrome c released into the cytosolreceptor blockers, was suspended in both ESRD patients
of PBMC was quantified by enzyme-linked immunosor-and healthy controls for at least one month before the
bent assay, previously validated by Western blot analysisbeginning of the study. When needed, blood pressure was
[9]. Anti-cytochrome c monoclonal antibodies (PharMin-kept under control with alternative drugs. We performed
gen, San Diego, CA), diluted 1:250, and goat anti-mousea two-step crossover study. In the first step, PBMC were
isolated from ESRD patients treated with CL-S filters be- immunoglobulins conjugated with alkaline phosphatase
fore and after a four-week treatment with a 1.3 square- (Bio-Rad Laboratories, Hercules, CA), diluted 1:2000,
meter Excebranemulti-layer vitamin E-coated cupram- were used as primary and secondary antibodies, respec-
monium rayon (CliransE15, CL-E) dialyzer, and then tively.
after another four-week washout with CL-S filters. In the
second step, PBMC were isolated from the same patients
RESULTStreated with CL-S filters before and after a four-week
treatment with oral vitamin E 600 mg/daily (Ephynal tabs, Apoptosis and mitochondrial damage in PBMC from
300 mg bid; Roche, Milan, Italy), and then after another ESRD patients
four-week washout with CL-S filters only. Both Clirans
PBMC from ESRD patients showed a maximum 3.3-S15 and CliransE15 membranes are brands from Ter-
fold increase in apoptotic body formation, compared toumo Corporation (Tokyo, Japan).
PBMC from healthy controls, after 48 hours of culture
Evaluation of cell death, mitochondrial uncoupling, (Table 1). However, in cells isolated from patients
and cytochrome c release treated with vitamin E (either filter-bound or supplied
orally) apoptotic bodies were only twofold higher thanPBMC (1 x 106/test) were isolated as described [4],
washed in phosphate-buffered saline, and cultured for in control PBMC (Table 1). Mononuclear cells from
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ESRD patients also showed mitochondrial uncoupling,
which reached a 3.5-fold maximum in healthy controls
after 4 hours, and increased cytochrome c release with
a threefold maximum after 8 hours of culture (Table 1).
Again, vitamin E prevented mitochondrial uncoupling
and cytochrome c release, regardless of its administration
route (Table 1). Moreover, 50 M vitamin E or 10 M
eicosatetraynoic acid (ETYA), a selective 5-lipoxygen-
ase inhibitor [6], significantly reduced apoptotic body
formation, mitochondrial uncoupling, and cytochrome c
release in mononuclear cells from post CL-S patients.
Conversely, 100 M indomethacin, a selective inhibitor
of cyclooxygenase, which converts arachidonic acid into
prostanoids [5], was ineffective (Table 1). Finally, in
PBMC of the post CL-S patients, the caspase-3 inhibitor
Z-DEVD-FMK [9] significantly reduced apoptosis, but
not mitochondrial uncoupling or cytochrome c release,
when used at 50 M (Table 1).
Fig. 1. Interplay between vitamin E, 5-lipoxygenase, mitochondrial
damage, and apoptosis of mononuclear cells. ESRD patients on mainte-DISCUSSION
nance HD show enhanced 5-lipoxygenase (5-LOX) activity in peripheral
Recently, we have shown that membrane lipid peroxi- blood mononuclear cells, which leads to increased membrane lipoperox-
ides and cytosolic reactive oxygen species (ROS), and to reduced mito-dation and cytosolic ROS formation occur in PBMC of
chondrial membrane potential (	). The increased cytochrome c (cyt c)ESRD patients on maintenance HD, mainly due to the release from mitochondria activates the caspase cascade, which, to-
activation of 5-lipoxygenase [4]. We have also shown that gether with lipoperoxide and ROS formation, triggers nuclear alter-
ations and ultimately leads to apoptosis. Oral or intramuscular (IM)in the same patients vitamin E prevents 5-lipoxygenase-
administration of vitamin E, as well as the filter-bound form, increasesmediated oxidative stress by directly inhibiting enzyme the plasma level of vitamin E, which prevents ESRD/HD-induced apo-
activity [4]. Activation of the lipoxygenase pathway has ptosis by directly inhibiting 5-LOX activity.
been associated to the early phase of PCD in several
mammalian cells [6]. Here, we extend these findings to
Prevention with Antioxidants of Cardiovascular Diseasemononuclear cells of uremic patients, where apoptosis
in Endstage Renal Disease (SPACE) study [10], which,has been observed [7], but not elucidated. Remarkably,
however, were neither confirmed in non-ESRD patients,PCD of mononuclear cells was paralleled by mitochon-
nor in the general population. Yet, the relatively simpledrial uncoupling and cytochrome c release (i.e., by dis-
experimental model of the study reported here (i.e.,ruption of mitochondrial integrity) (Table 1), which is
ESRD patients versus non-ESRD healthy subjects) didconsistent with the reported ability of lipoxygenase to
not take into account any concurrent cardiovascular dis-make “pore-like” structures in organelle membranes [9].
ease; further investigations are deemed necessary to as-Moreover, cytochrome c release usually triggers caspase
certain whether 5-lipoxygenase activation and subse-activation, a common step in several unrelated apoptotic
quent apoptosis, if ever present, are related to this typepathways, and indeed, inhibition of caspase-3, which is
of pathologic condition. In conclusion, these data mightupstream of the caspase cascade [6, 9], blocked cell death
be relevant for the treatment of various oxidative stress-(Table 1). Taken together, it can be proposed that activa-
related diseases that still account for a significant morbid-tion of 5-lipoxygenase is pivotal in the execution of apo-
ity and mortality among ESRD patients [11].ptosis in PBMC from ESRD patients, according to the
scheme depicted in Figure 1. The scheme also shows that
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